Condition: Friedreich's Ataxia (FA) · Sponsor: Solid Biosciences Inc.
This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.
This description comes directly from the study's public registry record.
Solid Biosciences Clinical Trials · +1617-337-4680 · clinicaltrials@solidbio.com
Always discuss trial participation with your own doctor first.
| The University of California, Los Angeles (UCLA) | Los Angeles, California, United States | Not Yet Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| The Children's Hospital of Philadelphia (CHOP) | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07180355